Molecular Neuroscience Group, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Brain. 2009 Nov;132(Pt 11):3102-21. doi: 10.1093/brain/awp240. Epub 2009 Sep 25.
Inhibition of central nervous system axon growth is reportedly mediated in part by calcium-dependent phosphorylation of axonal epidermal growth factor receptor, with local administration of the epidermal growth factor receptor kinase inhibitors AG1478 and PD168393 to an optic nerve lesion site promoting adult retinal ganglion cell axon regeneration. Here, we show that epidermal growth factor receptor was neither constitutively expressed, nor activated in optic nerve axons in our non-regenerating and regenerating optic nerve injury models, a finding that is inconsistent with phosphorylated epidermal growth factor receptor-dependent intra-axonal signalling of central nervous system myelin-related axon growth inhibitory ligands. However, epidermal growth factor receptor was localized and activated within most glia in the retina and optic nerve post-injury, and thus an indirect glial-dependent mechanism for stimulated retinal ganglion cell axon growth by epidermal growth factor receptor inhibitors seemed plausible. Using primary retinal cultures with added central nervous system myelin extracts, we confirmed previous reports that AG1478/PD168393 blocks epidermal growth factor receptor activation and promotes disinhibited neurite outgrowth. Paradoxically, neurites did not grow in central nervous system myelin extract-containing cultures after short interfering ribonucleic acid-mediated knockdown of epidermal growth factor receptor. However, addition of AG1478 restored neurite outgrowth to short interfering ribonucleic acid-treated cultures, implying that epidermal growth factor receptor does not mediate AG1478-dependent effects. TrkA-/B-/C-Fc fusion proteins and the kinase blocker K252a abrogated the neuritogenic activity in these cultures, correlating with the presence of the neurotrophins brain derived neurotrophic factor, nerve growth factor and neurotrophin-3 in the supernatant and increased intracellular cyclic adenosine monophosphate activity. Neurotrophins released by AG1478 stimulated disinhibited retinal ganglion cell axon growth in central nervous system myelin-treated cultures by the induction of regulated intramembraneous proteolysis of p75(NTR) and Rho inactivation. Retinal astrocytes/Müller cells and retinal ganglion cells were the source of neurotrophins, with neurite outgrowth halved in the presence of glial inhibitors. We attribute AG1478-stimulated neuritogenesis to the induced release of neurotrophins together with raised cyclic adenosine monophosphate levels in treated cultures, leading to axon growth and disinhibition by neurotrophin-induced regulated intramembraneous proteolysis of p75(NTR). These off-target effects of epidermal growth factor receptor kinase inhibition suggest a novel therapeutic approach for designing treatments to promote central nervous system axon regeneration.
据报道,中枢神经系统轴突生长的抑制作用部分是通过钙依赖性磷酸化轴突表皮生长因子受体介导的,局部给予视神经损伤部位表皮生长因子受体激酶抑制剂 AG1478 和 PD168393 可促进成年视网膜神经节细胞轴突再生。在这里,我们表明,表皮生长因子受体在我们的非再生和再生视神经损伤模型中的视神经轴突中既没有组成性表达,也没有被激活,这一发现与中枢神经系统髓鞘相关轴突生长抑制性配体的磷酸化表皮生长因子受体依赖性轴内信号不一致。然而,表皮生长因子受体在损伤后视网膜和视神经中的大多数神经胶质细胞中被定位和激活,因此,表皮生长因子受体抑制剂通过刺激视网膜神经节细胞轴突生长的间接胶质依赖性机制似乎是合理的。使用添加中枢神经系统髓鞘提取物的原代视网膜培养物,我们证实了以前的报告,即 AG1478/PD168393 阻断表皮生长因子受体的激活并促进去抑制的神经突生长。矛盾的是,在用短发夹 RNA 介导的表皮生长因子受体敲低后,神经突在含有中枢神经系统髓鞘提取物的培养物中没有生长。然而,AG1478 的添加恢复了短发夹 RNA 处理的培养物中的神经突生长,这意味着表皮生长因子受体不介导 AG1478 依赖性效应。TrkA-/B-/C-Fc 融合蛋白和激酶抑制剂 K252a 消除了这些培养物中的神经突生成活性,这与神经营养因子脑源性神经营养因子、神经生长因子和神经营养因子-3 在上清液中的存在以及细胞内环磷酸腺苷活性的增加相关。AG1478 释放的神经营养因子通过诱导 p75(NTR)的调节性跨膜蛋白水解和 Rho 失活来刺激中枢神经系统髓鞘处理的培养物中去抑制的视网膜神经节细胞轴突生长。视网膜星形胶质细胞/ Muller 细胞和视网膜神经节细胞是神经营养因子的来源,在存在神经胶质抑制剂的情况下,神经突生长减少了一半。我们将 AG1478 刺激的神经突发生归因于诱导释放神经营养因子以及处理培养物中环磷酸腺苷水平升高,导致轴突生长和由神经营养因子诱导的 p75(NTR)的调节性跨膜蛋白水解引起的去抑制。表皮生长因子受体激酶抑制的这些非靶向作用表明,设计治疗方法以促进中枢神经系统轴突再生是一种新的治疗方法。